Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EPS (Weighted Average and Diluted) (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.65 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 38.3% year-over-year to -$0.65; the TTM value through Sep 2025 reached $0.68, up 132.38%, while the annual FY2024 figure was -$1.65, 30.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.65 in Q3 2025 per STOK's latest filing, down from -$0.4 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.9 in Q1 2025 and bottomed at -$1.31 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.43, with a median of -$0.57 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 433.33% in 2025, down 38.3% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.31 in 2022, then surged by 54.2% to -$0.6 in 2023, then surged by 71.67% to -$0.17 in 2024, then crashed by 282.35% to -$0.65 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.65 in Q3 2025, -$0.4 in Q2 2025, and $1.9 in Q1 2025.